Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AUTL Autolus Therapeutics	$2.31	$1.73	$1.11 ▼ $5.00	$614.79M	1.76	1.58 million shs	2.09 million shs
LCTX Lineage Cell Therapeutics	$0.94 -3.0%	$0.64	$0.37 ▼ $1.15	$213.56M	1.52	1.55 million shs	23.64 million shs
RLAY Relay Therapeutics	$3.30 -0.6%	$3.13	$1.78 ▼ $10.72	$565.77M	1.59	2.09 million shs	2.08 million shs
SNDL SNDL	$1.23 -1.6%	$1.32	$1.22 ▼ $2.40	$323.21M	3.45	1.95 million shs	973,902 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AUTL Autolus Therapeutics	0.00%	+12.68%	+32.00%	+39.16%	-31.25%
LCTX Lineage Cell Therapeutics	0.00%	-1.56%	+36.33%	+90.12%	+3.55%
RLAY Relay Therapeutics	0.00%	+3.45%	+7.14%	+21.32%	-47.28%
SNDL SNDL	0.00%	-1.60%	-5.38%	-15.17%	-35.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AUTL Autolus Therapeutics	2.7169 of 5 stars	3.5	1.0	2.7	3.3	0.6
LCTX Lineage Cell Therapeutics	2.4432 of 5 stars	3.5	1.0	1.8	3.3	0.6
RLAY Relay Therapeutics	2.8902 of 5 stars	3.4	2.0	3.4	2.5	0.6
SNDL SNDL	3.783 of 5 stars	3.5	5.0	2.7	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AUTL Autolus Therapeutics	3.00	Buy	$9.32	303.46% Upside
LCTX Lineage Cell Therapeutics	3.00	Buy	$4.20	349.10% Upside
RLAY Relay Therapeutics	2.83	Moderate Buy	$17.67	435.35% Upside
SNDL SNDL	3.00	Buy	$3.63	194.72% Upside

Current Analyst Ratings Breakdown

Latest LCTX, SNDL, AUTL, and RLAY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/23/2025	LCTX Lineage Cell Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$2.00
6/23/2025	LCTX Lineage Cell Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
5/7/2025	RLAY Relay Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $10.00
4/17/2025	RLAY Relay Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$4.00
4/10/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/1/2025	AUTL Autolus Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00

(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AUTL Autolus Therapeutics	$10.12M	60.75	N/A	N/A	$1.61 per share	1.43
LCTX Lineage Cell Therapeutics	$9.50M	22.48	N/A	N/A	$0.35 per share	2.67
RLAY Relay Therapeutics	$10.01M	56.52	N/A	N/A	$4.65 per share	0.71
SNDL SNDL	$671.81M	0.48	N/A	N/A	$3.15 per share	0.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AUTL Autolus Therapeutics	-$220.66M	-$0.88	N/A	N/A	N/A	N/A	-52.82%	-29.67%	8/8/2025 (Estimated)
LCTX Lineage Cell Therapeutics	-$18.61M	-$0.12	N/A	N/A	N/A	-169.57%	-22.64%	-15.27%	8/6/2025 (Estimated)
RLAY Relay Therapeutics	-$337.71M	-$2.23	N/A	N/A	N/A	N/A	-44.17%	-39.53%	8/5/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.29	N/A	N/A	N/A	-11.48%	-9.02%	-7.60%	7/30/2025 (Estimated)

Latest LCTX, SNDL, AUTL, and RLAY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million
5/5/2025	Q1 2025	RLAY Relay Therapeutics	-$0.50	-$0.46	+$0.04	-$0.46	$0.01 million	$7.68 million
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
LCTX Lineage Cell Therapeutics	N/A	N/A	N/A	N/A	N/A
RLAY Relay Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AUTL Autolus Therapeutics	N/A	9.24	9.02
LCTX Lineage Cell Therapeutics	N/A	3.82	3.82
RLAY Relay Therapeutics	N/A	19.96	19.96
SNDL SNDL	0.10	4.62	3.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AUTL Autolus Therapeutics	72.83%
LCTX Lineage Cell Therapeutics	62.47%
RLAY Relay Therapeutics	96.98%
SNDL SNDL	N/A

Insider Ownership

Company	Insider Ownership
AUTL Autolus Therapeutics	25.70%
LCTX Lineage Cell Therapeutics	26.80%
RLAY Relay Therapeutics	4.87%
SNDL SNDL	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
LCTX Lineage Cell Therapeutics	60	228.36 million	167.16 million	Not Optionable
RLAY Relay Therapeutics	330	171.45 million	163.10 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable

LCTX, SNDL, AUTL, and RLAY Headlines

Recent News About These Companies

SNDL Inc. Announces Virtual Annual and Special Shareholders Meeting for July 2025

June 20, 2025 | tipranks.com

3 Cannabis Stocks For Investors To Secure For Future Gains

June 20, 2025 | marijuanastocks.comM

1CM Receives Court Approval for Arrangement with SNDL Inc

June 18, 2025 | newsfilecorp.comN

1CM Inc. Gains Court Approval for SNDL Arrangement

June 18, 2025 | tipranks.com

HYTN Receives Initial International Purchase Order for GMP Vape Cartridges

June 11, 2025 | finance.yahoo.com

Marijuana Stocks To Watch With Strong Market Potential

June 6, 2025 | marijuanastocks.comM

1CM Mails Circular for Annual and Special Meeting of Shareholders and Announces Receipt of Interim Court Order

May 20, 2025 | finance.yahoo.com

Canadian Securities Exchange Reports April 2025 Performance Figures

May 15, 2025 | finance.yahoo.com

SA analyst downgrades: KO, SNDL, MKL, KTOS, CAKE, CBRE, OLLI

May 5, 2025 | msn.com

SNDL Inc. Reports Record Profit Margins For Q1 2025, But Investor Risk Has Increased

May 5, 2025 | seekingalpha.com

SNDL Inc. (NASDAQ:SNDL) Q1 2025 Earnings Call Transcript

May 3, 2025 | insidermonkey.com

SNDL First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag

May 3, 2025 | finance.yahoo.com

3 Marijuana Stocks For The Long Term Investing

May 2, 2025 | marijuanastocks.comM

SNDL Inc (SNDL) Q1 2025 Earnings Call Highlights: Record Gross Margin and Strategic US Market Review

May 2, 2025 | uk.finance.yahoo.com

These Cannabis Companies Are Repurchasing Shares

May 2, 2025 | newcannabisventures.comN

SNDL Inc. (SNDL) Q1 2025 Earnings Call Transcript

May 2, 2025 | seekingalpha.com

SNDL 1Q Loss Widens

May 2, 2025 | marketwatch.com

SNDL Inc. Earnings Call Highlights Growth and Challenges

May 1, 2025 | tipranks.com

SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates

May 1, 2025 | zacks.com

SNDL Reports Record Q1 2025 Results and Strategic Initiatives

May 1, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LCTX, SNDL, AUTL, and RLAY Company Descriptions

Autolus Therapeutics NASDAQ:AUTL

$2.31 0.00 (0.00%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$2.32 +0.01 (+0.39%)

As of 06/27/2025 07:34 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Lineage Cell Therapeutics NYSEAMERICAN:LCTX

$0.94 -0.03 (-3.02%)

Closing price 06/27/2025 04:10 PM Eastern

Extended Trading

$0.98 +0.05 (+5.33%)

As of 06/27/2025 07:56 PM Eastern

Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.

Relay Therapeutics NASDAQ:RLAY

$3.30 -0.02 (-0.60%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.30 0.00 (0.00%)

As of 06/27/2025 05:25 PM Eastern

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

SNDL NASDAQ:SNDL

$1.23 -0.02 (-1.60%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.23 0.00 (0.00%)

As of 06/27/2025 07:53 PM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time